Intermediate Results of Prospective, Randomized, Comparative Study of NHL BFM-90 and СНОЕР Efficacy in Primary ALK-Positive Anaplastic Large-Cell Lymphoma

LG Gorenkova1, SK Kravchenko1, EE Klebanova1, AM Kovrigina1, KA Sychevskaya1, EG Gemdzhian1, ES Nesterova1, YaK Mangasarova1, AU Magomedova1, AV Misyurin2, YuV Sidorova1, TN Obukhova1

1 National Research Center for Hematology, 4 Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167

2 NN Blokhin National Medical Cancer Research Center, 24 Kashirskoye sh., Moscow, Russian Federation, 115478

For correspondence: Liliya Gamilevna Gorenkova, MD, PhD, 4 Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167; e-mail: l.aitova@mail.ru

For citation: Gorenkova LG, Kravchenko SK, Klebanova EE, et al. Intermediate Results of Prospective, Randomized, Comparative Study of NHL BFM-90 and СНОЕР Efficacy in Primary ALK-Positive Anaplastic Large-Cell Lymphoma. Clinical oncohematology. 2020;13(4):382–8. (In Russ).

DOI: 10.21320/2500-2139-2020-13-4-382-388


ABSTRACT

Aim. To compare NHL BFM-90 and CHOEP efficacy in adult patients with ALK-positive anaplastic large-cell lymphoma (ALK+ ALCL).

Materials & Methods. Within the period from June 2014 to December 2019 the prospective randomized comparative study at the National Research Center for Hematology in Moscow included 23 ALK+ ALCL patients. In one study arm (n = 11) CHOEP was administered, whereas the other one (n = 12) received high-dose chemotherapy (CT) according to NHL BFM-90 protocol. The median age of patients in both arms was 33 and 40 years, respectively.

Results. Overall survival (OS) and event-free survival (EFS) within 3 years were 91 % in the arm receiving CHOEP (this protocol was administered to all 11 patients), and 100 % in the arm receiving NHL BFM-90 (complete remission was achieved in all patients). Due to its toxicity NHL BFM-90 was fully implemented in 9 out of 12 patients. The 3-year OS and EFS in the CHOEP and NHL BFM-90 arms are comparable, and the difference between them is not significant.

Conclusion. In ALK+ ALCL treatment high-dose CT according to NHL BFM-90 protocol has no advantage in terms of the 3-year OS and EFS compared to less toxic regimen CHOEP. A larger sample of patients is required to achieve significant results, which will further lead to a final judgement on feasibility of high-dose regimens in the treatment of adult patients with ALK+ ALCL.

Keywords: ALK-positive anaplastic large-cell lymphoma, ALK+ ALCL, treatment, adults, CHOEP, NHL BFM-90, survival.

Received: April 8, 2020

Accepted: August 30, 2020

Read in PDF


REFERENCES

  1. Gorenkova L, Kravchenko S, Misurin A, et al. New characteristics of translocation in anaplastic large T-cell ALK-positive lymphoma. Blood. 2012;120(21):4419. doi: 10.1182/blood.v120.21.4419.4419.

  2. Stein H, Mason DY, Gerdes J, et al. The expression of the Hodgkin’s disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: Evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood. 1985;66(4):848–58. doi: 10.1182/blood.v66.4.848.848.

  3. Stansfeld AG, Diebold J, Noel H, et al. Updated Kiel classification for lymphomas. Lancet. 1988;331(8580):292–3. doi: 10.1016/s0140-6736(88)90367-4.

  4. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood. 1994;84(5):1361–92. doi: 10.1182/blood.v84.5.1361.1361.

  5. Swerdlow SH, Campo E, Harris NL, et al. (eds) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised 4th edition. Lyon: IARC Press; 2017.

  6. O’Connor NT, Stein H, Gatter KC, et al. Genotypic analysis of large cell lymphomas which express the Ki-1 antigen. Histopathology. 1987;11(7):733–40. doi: 10.1111/j.1365-2559.1987.tb02687.x.

  7. Herbst H, Tippelmann G, Anagnostopoulos I, et al. Immunoglobulin and T-cell receptor gene rearrangements in Hodgkin’s disease and Ki-1-positive anaplastic large cell lymphoma: Dissociation between phenotype and genotype. Leuk Res. 1989,13(2):103–16. doi: 10.1016/0145-2126(89)90134-3.

  8. Morris SW, Kirstein MN, Valentine MB, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphoma. Science. 1994;263(5151):1281–4. doi: 10.1126/science.8122112.

  9. Swerdlow SH, Campo E, Harris N, et al. (eds) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th edition. Lyon: IARC Press; 2008. Vol. 2.

  10. Savage KJ, Harris NL, Vose JM, et al. ALK– anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: Report from the International Peripheral T-Cell Lymphoma Project. Blood. 2008;111(12):5496–504. doi: 10.1182/blood-2008-01-134270.

  11. Falini B, Pileri S, Zinzani, PL, et al. ALK+ lymphoma: Clinico-pathological findings and outcome. Blood. 1999;93(8):2697–706. doi: 10.1182/blood.V93.8.2697.408k25_2697_2706.

  12. Stein H, Foss HD, Durkop H, et al. CD30(+) anaplastic large cell lymphoma: A review of its histopathologic, genetic, and clinical features. Blood. 2000;96(12):3681–95.

  13. Filippa DA, Ladanyi M, Wollner N, et al. CD30 (Ki-1)-positive malignant lymphomas: Clinical, immunophenotypic, histologic, and genetic characteristics and differences with Hodgkin’s disease. Blood. 1996;87(7):2905–17. doi: 10.1182/blood.v87.7.2905.bloodjournal8772905.

  14. Kadin ME, Carpenter C. Systemic and primary cutaneous anaplastic large cell lymphomas. Semin Hematol. 2003;40(3):244–56. doi: 10.1016/s0037-1963(03)00138-0.

  15. Ellin F, Landstrom J, Jerkeman M, Relander T. Central nervous system relapse in peripheral T-cell lymphomas: A Swedish Lymphoma Registry study. Blood. 2015;126(1):36–41. doi: 10.1182/blood-2014-12-616961.

  16. Nomura M, Narita Y, Miyakita Y, et al. Clinical presentation of anaplastic large-cell lymphoma in the central nervous system. Mol Clin Oncol. 2013;1(4):655–60. doi: 10.3892/mco.2013.110.

  17. Williams D, Mori T, Reiter A, et al. Central nervous system involvement in anaplastic large cell lymphoma in childhood: Results from a multicentre European and Japanese study. Pediatr Blood Cancer. 2013;60(10):E118–Е121. doi: 10.1002/pbc.24591.

  18. Onciu M, Behm FG, Raimondi SC, et al. ALK-positive anaplastic large cell lymphoma with leukemic peripheral blood involvement is a clinicopathologic entity with an unfavorable prognosis. Report of three cases and review of the literature. Am J Clin Pathol. 2003;120(4):617–25. doi: 10.1309/wh8pnu9pk4rrv852.

  19. Spiegel A, Paillard C, Ducassou S, et al. Paediatric anaplastic large cell lymphoma with leukaemic presentation in children: A report of nine French cases. Br J Haematol. 2014;165(4):545–51. doi: 10.1111/bjh.12777.

  20. Mussolin L, Pillon M, d’Amore ES, et al. Prevalence and clinical implications of bone marrow involvement in pediatric anaplastic large cell lymphoma. 2005;19(9):1643–7. doi: 10.1038/sj.leu.2403888.

  21. Damm-Welk C, Mussolin L, Zimmermann M, et al. Early assessment of minimal residual disease identifies patients at very high relapse risk in NPM-ALK-positive anaplastic large-cell lymphoma. 2014;123(3):334–7. doi: 10.1182/blood-2013-09-526202.

  22. Горенкова Л.Г., Кравченко С.К., Мисюрин А.В. и др. Клиническая и молекулярная оценки эффективности высокодозной химиотерапии при анаплазированной Т-крупноклеточной АЛК-позитивной лимфоме у взрослых. Гематология и трансфузиология. 2012;57(S3):43. [Gorenkova LG, Kravchenko SK, Misyurin AV, et al. Clinical and molecular evaluation of the efficacy of high-dose chemotherapy in adult patients with anaplastic large T-cell ALK-positive lymphoma. Gematologiya i transfuziologiya. 2012;57(S3):43. (In Russ)]

  23. Tsuyama N, Sakamoto K, Sakata S, et al. Anaplastic Large Cell Lymphoma: Pathology, Genetics, and Clinical Aspect. J Clin Exp Hematop. 2017;57(3):120–42. doi: 10.3960/jslrt.17023.

  24. Brugieres L, Deley MC, Pacquement H, et al. CD30(+) anaplastic large-cell lymphoma in children: Analysis of 82 patients enrolled in two consecutive studies of the French Society of Pediatric Oncology. Blood. 1998;92(10):3591–8. doi: 1182/blood.V92.10.3591.

  25. Rosolen A, Pillon M, Garaventa A, et al. Anaplastic large cell lymphoma treated with a leukemia-like therapy: Report of the Italian Association of Pediatric Hematology and Oncology (AIEOP) LNH-92 protocol. Cancer. 2005;104(10):2133–40. doi: 10.1002/cncr.21438.

  26. Seidemann K, Tiemann M, Schrappe M, et al. Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: A report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM 90. Blood. 2001;97(12):3699–706. doi: 10.1182/blood.v97.12.3699.

  27. Schmitz N, Trumper L, Ziepert M, et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood. 2010;116(18):3418–25. doi: 10.1182/blood-2010-02-270785.

  28. Brugieres L, Le Deley MC, Rosolen A, et al. Impact of the methotrexate administration dose on the need for intrathecal treatment in children and adolescents with anaplastic large-cell lymphoma: results of a randomized trial of the EICNHL Group. J Clin Oncol. 2009;27(6):897–903. doi: 10.1200/jco.2008.18.1487.

  29. Wrobel G, Mauguen A, Rosolen A, et al. European Inter-Group for Childhood, Non-Hodgkin Lymphoma (EICNHL). Safety assessment of intensive induction therapy in childhood anaplastic large cell lymphoma: report of the ALCL99 randomised trial. Pediatr Blood Cancer. 2011;56(7):1071–7. doi: 10.1002/pbc.22940.

  30. Oeffinger KC, Mertens AC, Sklar CA, et al. Chronic Health Conditions in Adult survivors of childhood cancer. N Engl J Med. 2006;355(15):1572–82. doi: 10.1056/nejmsa060185.

  31. Gorenkova L, Kravchenko SK, Kovrigina AM, et al. Late Events In Adult Patients With ALK-Positive Anaplastic Large Cell Lymphoma. 2017;130(S1):5176.

  32. Горенкова Л.Г., Кравченко С.К., Ковригина А.М. и др. Анапластические крупноклеточные лимфомы взрослых: влияние цитогенетических и молекулярно-генетических характеристик на результаты лечения (собственный опыт одного института). Гематология и трансфузиология. 2018;63(S1):56–7. [Gorenkova LG, Kravchenko SK, Kovrigina AM, et al. Anaplastic large-cell lymphomas in adult patients: effect of cytogenetic and molecular genetic characteristics on treatment outcomes (a single-institution experience). Gematologiya i transfuziologiya. 2018;63(S1):56–7. (In Russ)]

  33. Горенкова Л.Г. Клиническая и молекулярная оценка эффективности высокодозной химиотерапии анапластической крупноклеточной АЛК-позитивной лимфомы взрослых: Автореф. дис. … канд. мед. наук. М., 2013. [Gorenkova LG. Klinicheskaya i molekulyarnaya otsenka effektivnosti vysokodoznoi khimioterapii anaplasticheskoi krupnokletochnoi ALK-pozitivnoi limfomy vzroslykh. (Clinical and molecular assessment of high-dose chemotherapy efficacy in adult patients with ALK-positive anaplastic large-cell ) [dissertation] Moscow; 2013. (In Russ)]

  34. Broccoli А, Zinzani PL. Peripheral T-cell lymphoma, not otherwise specified. Blood. 2017;129(9):1103–12. doi: 10.1182/blood-2016-08-692566.